MGX (Metagenomi Therapeutics) E10: $0.00 (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.25
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics E10?

Metagenomi Therapeutics MGX +3.31% 10 E10 is $0.00 as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Metagenomi Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was $-2.360. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Metagenomi Therapeutics's current stock price is $ 1.25. Metagenomi Therapeutics's E10 for the fiscal year that ended in Dec. 2025 was $0.00. Metagenomi Therapeutics's Shiller PE Ratio of today is .


Metagenomi Therapeutics  (NAS:MGX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Metagenomi Therapeutics E10 Related Terms


Metagenomi Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics E10 Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
E10
0.00 0.00 0.00 0.00 0.00

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MGX vs HYPD, ATYR, ACTU: E10 Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metagenomi Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's Shiller PE Ratio falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Metagenomi Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-2.36/324.0540*324.0540
=-2.360

Current CPI (Dec. 2025) = 324.0540.

Metagenomi Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate it.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
Metagenomi Therapeutics (MGX) has a E10 of $0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' E10 too high?
Metagenomi Therapeutics' current E10 is $0.00. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' E10 compare to HYPD and ATYR?
Metagenomi Therapeutics' E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current E10 of $0.00. The current E10 is $0.00. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current E10 is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price